News Oxford BioMedica could get $100m following CAR-T approval UK biotech will supply key component of Novartis' newly approved cancer cell therapy
News Oxford BioMedica signs $100m CAR-T deal with Novartis UK firm to supply viruses to generate CAR-T therapies
News Disappointment for BMS as Zeposia fails Crohn’s study Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.